AR107132A1 - Cocristal, método de producción del mismo, y medicamento que contiene dicho cocristal - Google Patents
Cocristal, método de producción del mismo, y medicamento que contiene dicho cocristalInfo
- Publication number
- AR107132A1 AR107132A1 ARP160103985A ARP160103985A AR107132A1 AR 107132 A1 AR107132 A1 AR 107132A1 AR P160103985 A ARP160103985 A AR P160103985A AR P160103985 A ARP160103985 A AR P160103985A AR 107132 A1 AR107132 A1 AR 107132A1
- Authority
- AR
- Argentina
- Prior art keywords
- crystal
- optionally substituted
- hooc
- formula
- group
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C55/00—Saturated compounds having more than one carboxyl group bound to acyclic carbon atoms
- C07C55/02—Dicarboxylic acids
- C07C55/08—Malonic acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
- C07C57/02—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms with only carbon-to-carbon double bonds as unsaturation
- C07C57/13—Dicarboxylic acids
- C07C57/145—Maleic acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
- C07C59/235—Saturated compounds containing more than one carboxyl group
- C07C59/245—Saturated compounds containing more than one carboxyl group containing hydroxy or O-metal groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
- C07C59/235—Saturated compounds containing more than one carboxyl group
- C07C59/245—Saturated compounds containing more than one carboxyl group containing hydroxy or O-metal groups
- C07C59/265—Citric acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
- C07C59/40—Unsaturated compounds
- C07C59/42—Unsaturated compounds containing hydroxy or O-metal groups
- C07C59/48—Unsaturated compounds containing hydroxy or O-metal groups containing six-membered aromatic rings
- C07C59/50—Mandelic acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
- C07C59/40—Unsaturated compounds
- C07C59/42—Unsaturated compounds containing hydroxy or O-metal groups
- C07C59/54—Unsaturated compounds containing hydroxy or O-metal groups containing six-membered aromatic rings and other rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C65/00—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
- C07C65/01—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing hydroxy or O-metal groups
- C07C65/03—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing hydroxy or O-metal groups monocyclic and having all hydroxy or O-metal groups bound to the ring
- C07C65/05—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing hydroxy or O-metal groups monocyclic and having all hydroxy or O-metal groups bound to the ring o-Hydroxy carboxylic acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C65/00—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
- C07C65/01—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing hydroxy or O-metal groups
- C07C65/03—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing hydroxy or O-metal groups monocyclic and having all hydroxy or O-metal groups bound to the ring
- C07C65/05—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing hydroxy or O-metal groups monocyclic and having all hydroxy or O-metal groups bound to the ring o-Hydroxy carboxylic acids
- C07C65/10—Salicylic acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Reivindicación 1: Un cocristal de (S)-3-(1-((1-acriloilpirrolidin-3-il)oxi)isoquinolin-3-il)-1H-1,2,4-triazol-5(4H)-ona y un ácido orgánico capaz de formar un cocristal con el compuesto mencionado con anterioridad. Reivindicación 2: El cocristal de acuerdo con la reivindicación 1, caracterizado porque el ácido orgánico es ácido carboxílico. Reivindicación 3: El cocristal de acuerdo con la reivindicación 2, caracterizado porque el ácido carboxílico es un compuesto representado por la fórmula (1): HOOC-R¹-X (1) en la que X es un grupo hidroxi o un grupo carboxi, y R¹ es un grupo divalente representado por la fórmula (2): * -C(R²) = C(R³)- ** (2) {en la que, R² y R³ son cada uno en forma independiente un átomo de hidrógeno o un grupo alquilo C₁₋₆ sustituido en forma opcional, están unidos entre sí para formar, junto con los átomos de carbono unidos a los mismos, un anillo de hidrocarburo C₆₋₁₄ sustituido en forma opcional, * es una posición de unión a HOOC, y ** es una posición de unión a X}, o un grupo divalente representado por la fórmula (3): * -C(R⁴)(R⁵)- ** (3) {en la que, R⁴ y R⁵ son cada uno en forma independiente un átomo de hidrógeno, un grupo alquilo C₁₋₆ sustituido en forma opcional, o un grupo arilo C₆₋₁₄ sustituido en forma opcional, * es una posición de unión a HOOC, y ** es una posición de unión a X}.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2015252658 | 2015-12-24 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR107132A1 true AR107132A1 (es) | 2018-03-21 |
Family
ID=57910088
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP160103985A AR107132A1 (es) | 2015-12-24 | 2016-12-22 | Cocristal, método de producción del mismo, y medicamento que contiene dicho cocristal |
Country Status (25)
| Country | Link |
|---|---|
| US (1) | US10836745B2 (es) |
| EP (1) | EP3394045B1 (es) |
| JP (1) | JP6876704B2 (es) |
| KR (1) | KR20180095933A (es) |
| CN (1) | CN108473467B (es) |
| AR (1) | AR107132A1 (es) |
| AU (1) | AU2016375899B2 (es) |
| CA (1) | CA3009610C (es) |
| CL (1) | CL2018001725A1 (es) |
| CO (1) | CO2018006473A2 (es) |
| DK (1) | DK3394045T3 (es) |
| EA (1) | EA039213B1 (es) |
| EC (1) | ECSP18055921A (es) |
| ES (1) | ES2877089T3 (es) |
| HK (1) | HK1256362A1 (es) |
| IL (1) | IL260195A (es) |
| MX (1) | MX2018007721A (es) |
| PH (1) | PH12018501356A1 (es) |
| PL (1) | PL3394045T3 (es) |
| SG (1) | SG11201805331QA (es) |
| TN (1) | TN2018000221A1 (es) |
| TW (1) | TWI722080B (es) |
| UY (1) | UY37046A (es) |
| WO (1) | WO2017111179A1 (es) |
| ZA (1) | ZA201804393B (es) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112020006674A2 (pt) * | 2017-10-06 | 2020-10-06 | Cargill, Incorporated | composição de glicosídeo de esteviol prontamente dissolvível, e, composição seca de glicosídeo de esteviol prontamente dissolvível |
| BR112020006587B1 (pt) * | 2017-10-06 | 2024-01-09 | Cargill, Incorporated | Solução aquosa de glicosídeo de esteviol, composição de bebida, adoçante, e, método para solubilizar uma composição total de glicosídeo de esteviol |
| BR112021019811A2 (pt) | 2019-04-06 | 2021-12-07 | Cargill Inc | Composição de glicosídeo de esteviol, bebida, métodos para reduzir um atributo sensorial indesejável de uma solução aquosa de glicosídeo de esteviol, para reduzir a persistência de doçura de um componente de glicosídeo de esteviol em uma composição comestível e para reduzir o amargor de um componente de glicosídeo de esteviol em uma composição comestível, e, soluções aquosa de glicosídeo de esteviol com reduzida persistência de doçura e aquosa de glicosídeo de esteviol com reduzido amargor |
| CN110818692B (zh) * | 2019-11-08 | 2023-03-24 | 中国海洋大学 | 一种替加氟与丁香酸的共晶及其制备方法 |
| US11578041B2 (en) * | 2020-04-21 | 2023-02-14 | Genovate Biotechnology Co. Ltd. | Crystals of hydroxychloroquine sulfate |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5376645A (en) | 1990-01-23 | 1994-12-27 | University Of Kansas | Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof |
| KR0166088B1 (ko) | 1990-01-23 | 1999-01-15 | . | 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도 |
| GB9518953D0 (en) | 1995-09-15 | 1995-11-15 | Pfizer Ltd | Pharmaceutical formulations |
| GB9711643D0 (en) | 1997-06-05 | 1997-07-30 | Janssen Pharmaceutica Nv | Glass thermoplastic systems |
| CO4940418A1 (es) | 1997-07-18 | 2000-07-24 | Novartis Ag | Modificacion de cristal de un derivado de n-fenil-2- pirimidinamina, procesos para su fabricacion y su uso |
| SK285190B6 (sk) | 1997-10-07 | 2006-08-03 | Schering Corporation | Kryštálová modifikácia proti plesniam a farmaceutický prostriedok s jej obsahom |
| US6608055B2 (en) | 2001-06-22 | 2003-08-19 | Boehringer Ingelheim Pharma Kg | Crystalline anticholinergic, processes for preparing it and its use for preparing a pharmaceutical composition |
| US6737432B2 (en) | 2001-10-31 | 2004-05-18 | Boehringer Ingelheim Pharma Kg | Crystalline form of telmisartan sodium |
| US7927613B2 (en) | 2002-02-15 | 2011-04-19 | University Of South Florida | Pharmaceutical co-crystal compositions |
| CN101541618A (zh) | 2007-02-28 | 2009-09-23 | 日本精工株式会社 | 倾斜式转向装置 |
| US7718662B1 (en) | 2009-10-12 | 2010-05-18 | Pharmacyclics, Inc. | Pyrazolo-pyrimidine inhibitors of bruton's tyrosine kinase |
| EP2507242A1 (en) | 2009-12-03 | 2012-10-10 | AstraZeneca AB | Co - crystals of a triazolo [4,5 - d]pyrimidine platelet aggregation inhibitor |
| WO2013010136A2 (en) | 2011-07-13 | 2013-01-17 | Pharmacyclics, Inc. | Inhibitors of bruton's tyrosine kinase |
| JO3377B1 (ar) * | 2013-03-11 | 2019-03-13 | Takeda Pharmaceuticals Co | مشتقات بيريدينيل وبيريدينيل مندمج |
-
2016
- 2016-12-22 AR ARP160103985A patent/AR107132A1/es unknown
- 2016-12-22 DK DK16831645.3T patent/DK3394045T3/da active
- 2016-12-22 EA EA201891467A patent/EA039213B1/ru unknown
- 2016-12-22 PL PL16831645T patent/PL3394045T3/pl unknown
- 2016-12-22 CN CN201680075516.XA patent/CN108473467B/zh active Active
- 2016-12-22 TW TW105142683A patent/TWI722080B/zh active
- 2016-12-22 ES ES16831645T patent/ES2877089T3/es active Active
- 2016-12-22 MX MX2018007721A patent/MX2018007721A/es unknown
- 2016-12-22 JP JP2018532473A patent/JP6876704B2/ja active Active
- 2016-12-22 SG SG11201805331QA patent/SG11201805331QA/en unknown
- 2016-12-22 WO PCT/JP2016/089224 patent/WO2017111179A1/en active Application Filing
- 2016-12-22 KR KR1020187021264A patent/KR20180095933A/ko active IP Right Grant
- 2016-12-22 EP EP16831645.3A patent/EP3394045B1/en active Active
- 2016-12-22 CA CA3009610A patent/CA3009610C/en active Active
- 2016-12-22 US US15/388,063 patent/US10836745B2/en active Active
- 2016-12-22 TN TNP/2018/000221A patent/TN2018000221A1/en unknown
- 2016-12-22 AU AU2016375899A patent/AU2016375899B2/en active Active
- 2016-12-22 UY UY0001037046A patent/UY37046A/es not_active Application Discontinuation
-
2018
- 2018-06-21 IL IL260195A patent/IL260195A/en unknown
- 2018-06-22 PH PH12018501356A patent/PH12018501356A1/en unknown
- 2018-06-22 CL CL2018001725A patent/CL2018001725A1/es unknown
- 2018-06-22 CO CONC2018/0006473A patent/CO2018006473A2/es unknown
- 2018-06-29 ZA ZA2018/04393A patent/ZA201804393B/en unknown
- 2018-07-24 EC ECSENADI201855921A patent/ECSP18055921A/es unknown
- 2018-12-03 HK HK18115451.0A patent/HK1256362A1/zh unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR107132A1 (es) | Cocristal, método de producción del mismo, y medicamento que contiene dicho cocristal | |
| CU24385B1 (es) | Compuestos éteres de arilo útiles para tratar cancer de célula renal | |
| AR111689A1 (es) | Tienopiridinas y benzotiofenos útiles como inhibidores de irak4 | |
| AR090203A1 (es) | Compuestos heterobiciclicos como inhibidores de pde10 | |
| AR102306A1 (es) | Esteroides neuroactivos útiles en el tratamiento de enfermedades del snc | |
| JO3581B1 (ar) | مركبات ميثيل-بيبيريدين جديدة مفيدة لتثبيط إنزيم سينثاز -1 بروستاجلاندين e2 ميكروسومي | |
| AR099177A1 (es) | Determinadas (2s)-n-[(1s)-1-ciano-2-feniletil]-1,4-oxazepan-2-carboxamidas como inhibidores de dipeptidil peptidasa 1 | |
| PE20180552A1 (es) | Nuevos compuestos biciclicos como inhibidores duales de atx/ca | |
| AR100315A1 (es) | Compuestos de piridina sustituida que tienen acción herbicida | |
| PE20151542A1 (es) | Compuestos de tetrahidropirrolotiazina | |
| AR094812A1 (es) | Derivado de piridina monocíclico como inhibidor del fgfr | |
| AR099489A1 (es) | 2-amino-3,5,5-trifluoro-3,4,5,6-tetrahidropiridinas como inhibidores de bace1 para el tratamiento de la enfermedad de alzheimer | |
| AR105668A1 (es) | 2-amino-3-fluoro-3-(fluorometil)-6-metil-6-fenil-3,4,5,6-tetrahidropiridinas como inhibidores de bace1 | |
| AR098522A1 (es) | Compuesto de triazolo-piridina | |
| AR101815A1 (es) | Compuestos y composiciones como inhibidores de quinasa | |
| AR097082A1 (es) | Compuestos terapéuticamente activos y sus métodos de uso | |
| CY1125319T1 (el) | Ιοντικες ενωσεις συγκρυσταλλου λιθιου οργανικου ανιοντος και συνθεσεις | |
| AR109711A1 (es) | Inhibidores de fosfatidilinositol 3-quinasa | |
| AR099047A1 (es) | Derivados etinilo | |
| AR100776A1 (es) | Compuestos herbicidas | |
| AR090086A1 (es) | COMPUESTO DE 1H-INDAZOL-3-CARBOXAMIDA COMO INHIBIDORES DE LA GLUCOGENO SINTASA CINASA 3 b | |
| AR095040A1 (es) | Antagonistas de h3 que contienen un núcleo estructural de fenoxipiperidina | |
| AR090566A1 (es) | Proceso para la produccion de inhibidores de crr | |
| AR097739A1 (es) | Imidazo[1,2-a]piridina-7-aminas | |
| AR104539A1 (es) | Compuestos cíclicos |